AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-60 (Canceled)

61. (Currently Amended) A method of ameliorating hepatic steatosis in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound ~~that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-III (SEQ ID NO: 4)~~ comprising 15 to 30 linked nucleosides, wherein the antisense compound is 100% complementary to SEQ ID NO: 4 and inhibits the expression of apolipoprotein C-III, so that hepatic steatosis is ameliorated.

62. -64.(Canceled)

65. (Currently Amended) The method of Claim [[64]] 61, wherein said ~~oligonucleotide~~ antisense compound ~~comprises~~ is a single-stranded ~~nucleotide~~ antisense oligonucleotide.

66. (Currently Amended) The method of Claim 65, wherein said ~~oligonucleotide~~ antisense compound comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.

67. (Previously presented) The method of Claim 66, wherein said modified internucleoside linkage is a phosphorothioate linkage.

68. (Previously presented) The method of Claim 66, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

69. (Previously presented) The method of Claim 66, wherein said modified nucleobase is a 5-methylcytosine.

70. (Currently Amended) A method of lowering liver tissue triglyceride levels in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound ~~that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-III (SEQ ID NO: 4),~~ comprising 15 to 30 linked nucleosides, wherein

said antisense compound is 100% complementary to SEQ ID NO: 4 and inhibits the expression of apolipoprotein C-III, ~~and~~ thereby ~~lowers~~ lowering liver tissue triglyceride levels.

71. (Canceled)

72. (Currently Amended) The method of Claim [[71]] 70, wherein said ~~oligonucleotide~~ antisense compound ~~comprises~~ is a single-stranded ~~nucleotide~~ antisense oligonucleotide.

73. (Currently Amended) The method of Claim 72, wherein said ~~oligonucleotide~~ antisense compound comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.

74. (Previously presented) The method of Claim 73, wherein said modified internucleoside linkage is a phosphorothioate linkage.

75. (Previously presented) The method of Claim 73, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

76. (Previously presented) The method of Claim 73, wherein said modified nucleobase is a 5-methylcytosine.

77.-83. (Canceled)

84. (New) The method of claim 61, wherein the administering comprises parenteral administration.

85. (New) The method of claim 84, wherein the parenteral administration comprises subcutaneous administration.

86. (New) The method of claim 61, wherein the antisense compound comprises a gap segment of linked 2'-deoxynucleotides positioned between a 5' wing segment of linked nucleosides and a 3' wing segment nucleosides, wherein each nucleoside of each wing segment comprises a modified sugar moiety.

87. (New) The method of claim 86, wherein the gap segment is ten linked 2'-deoxynucleotides and each wing segment is five linked 2'-O-methoxyethyl nucleotides.

88. (New) The method of claim 87, wherein each internucleoside linkage is a

phosphorothioate internucleoside linkage.

89. (New) The method of claim 88, wherein the antisense compound comprises 5-methylcytosines.

90. (New) The method of claim 61, wherein the animal is a human.

91. (New) The method of claim 90, further comprising selecting a human having hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, type 2 diabetes, or obesity.

92. (New) The method of claim 70, wherein the administering comprises parenteral administration.

93. (New) The method of claim 92, wherein the parenteral administration comprises subcutaneous administration.

94. (New) The method of claim 70, wherein the antisense compound comprises a gap segment of linked 2'-deoxynucleotides positioned between a 5' wing segment of linked nucleosides and a 3' wing segment nucleosides, wherein each nucleoside of each wing segment comprises a modified sugar moiety.

95. (New) The method of claim 94, wherein the gap segment is ten linked 2'-deoxynucleotides and each wing segment is five linked 2'-O-methoxyethyl nucleotides.

96. (New) The method of claim 95, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

97. (New) The method of claim 96, wherein the antisense compound comprises 5-methylcytosines.

98. (New) The method of claim 70, wherein the animal is a human.

99. (New) The method of claim 98, further comprising selecting a human having hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, type 2 diabetes, or obesity.